Literature DB >> 20574456

The de-ubiquitinase UCH-L1 is an oncogene that drives the development of lymphoma in vivo by deregulating PHLPP1 and Akt signaling.

S Hussain1, O Foreman, S L Perkins, T E Witzig, R R Miles, J van Deursen, P J Galardy.   

Abstract

De-ubiquitinating enzymes (DUBs) can reverse the modifications catalyzed by ubiquitin ligases and as such are believed to be important regulators of a variety of cellular processes. Several members of this protein family have been associated with human cancers; however, there is little evidence for a direct link between deregulated de-ubiquitination and neoplastic transformation. Ubiquitin C-terminal hydrolase (UCH)-L1 is a DUB of unknown function that is overexpressed in several human cancers, but whether it has oncogenic properties has not been established. To address this issue, we generated mice that overexpress UCH-L1 under the control of a ubiquitous promoter. Here, we show that UCH-L1 transgenic mice are prone to malignancy, primarily lymphomas and lung tumors. Furthermore, UCH-L1 overexpression strongly accelerated lymphomagenesis in Emu-myc transgenic mice. Aberrantly expressed UCH-L1 boosts signaling through the Akt pathway by downregulating the antagonistic phosphatase PHLPP1, an event that requires its de-ubiquitinase activity. These data provide the first in vivo evidence for DUB-driven oncogenesis and suggest that UCH-L1 hyperactivity deregulates normal Akt signaling.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20574456      PMCID: PMC3236611          DOI: 10.1038/leu.2010.138

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  61 in total

1.  Substrate specificity of deubiquitinating enzymes: ubiquitin C-terminal hydrolases.

Authors:  C N Larsen; B A Krantz; K D Wilkinson
Journal:  Biochemistry       Date:  1998-03-10       Impact factor: 3.162

2.  The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase.

Authors:  K D Wilkinson; K M Lee; S Deshpande; P Duerksen-Hughes; J M Boss; J Pohl
Journal:  Science       Date:  1989-11-03       Impact factor: 47.728

3.  The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase.

Authors:  T F Franke; S I Yang; T O Chan; K Datta; A Kazlauskas; D K Morrison; D R Kaplan; P N Tsichlis
Journal:  Cell       Date:  1995-06-02       Impact factor: 41.582

4.  Protamine-Cre recombinase transgenes efficiently recombine target sequences in the male germ line of mice, but not in embryonic stem cells.

Authors:  S O'Gorman; N A Dagenais; M Qian; Y Marchuk
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205

5.  PGP9.5 as a candidate tumor marker for non-small-cell lung cancer.

Authors:  K Hibi; W H Westra; M Borges; S Goodman; D Sidransky; J Jen
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

6.  Role of translocation in the activation and function of protein kinase B.

Authors:  M Andjelković; D R Alessi; R Meier; A Fernandez; N J Lamb; M Frech; P Cron; P Cohen; J M Lucocq; B A Hemmings
Journal:  J Biol Chem       Date:  1997-12-12       Impact factor: 5.157

7.  The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice.

Authors:  J M Adams; A W Harris; C A Pinkert; L M Corcoran; W S Alexander; S Cory; R D Palmiter; R L Brinster
Journal:  Nature       Date:  1985 Dec 12-18       Impact factor: 49.962

8.  The American Burkitt's Lymphoma Registry: eight years' experience.

Authors:  P H Levine; L S Kamaraju; R R Connelly; C W Berard; R F Dorfman; I Magrath; J M Easton
Journal:  Cancer       Date:  1982-03-01       Impact factor: 6.860

9.  Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells.

Authors:  R Dalla-Favera; M Bregni; J Erikson; D Patterson; R C Gallo; C M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

10.  The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells.

Authors:  A W Harris; C A Pinkert; M Crawford; W Y Langdon; R L Brinster; J M Adams
Journal:  J Exp Med       Date:  1988-02-01       Impact factor: 14.307

View more
  60 in total

1.  Suppression of survival signalling pathways by the phosphatase PHLPP.

Authors:  Audrey K O'Neill; Matthew J Niederst; Alexandra C Newton
Journal:  FEBS J       Date:  2012-03-16       Impact factor: 5.542

2.  Prognostic relevance of ubiquitin C-terminal hydrolase L1 (UCH-L1) mRNA and protein expression in breast cancer patients.

Authors:  Christine Schröder; Karin Milde-Langosch; Florian Gebauer; Katharina Schmid; Volkmar Mueller; Ralph M Wirtz; Catherine Meyer-Schwesinger; Hartmut Schlüter; Guido Sauter; Udo Schumacher
Journal:  J Cancer Res Clin Oncol       Date:  2013-08-31       Impact factor: 4.553

3.  The co-crystal structure of ubiquitin carboxy-terminal hydrolase L1 (UCHL1) with a tripeptide fluoromethyl ketone (Z-VAE(OMe)-FMK).

Authors:  Christopher W Davies; Joseph Chaney; Gregory Korbel; Dagmar Ringe; Gregory A Petsko; Hidde Ploegh; Chittaranjan Das
Journal:  Bioorg Med Chem Lett       Date:  2012-05-04       Impact factor: 2.823

4.  Role of growth arrest and DNA damage-inducible α in Akt phosphorylation and ubiquitination after mechanical stress-induced vascular injury.

Authors:  Sumegha Mitra; Saad Sammani; Ting Wang; David L Boone; Nuala J Meyer; Steven M Dudek; Liliana Moreno-Vinasco; Joe G N Garcia; Jeffrey R Jacobson
Journal:  Am J Respir Crit Care Med       Date:  2011-11-01       Impact factor: 21.405

5.  Ubiquitin C-Terminal Hydrolase L1: Biochemical and Cellular Characterization of a Covalent Cyanopyrrolidine-Based Inhibitor.

Authors:  Aaron D Krabill; Hao Chen; Sajjad Hussain; Chao Feng; Ammara Abdullah; Chittaranjan Das; Uma K Aryal; Carol Beth Post; Michael K Wendt; Paul J Galardy; Daniel P Flaherty
Journal:  Chembiochem       Date:  2019-11-07       Impact factor: 3.164

Review 6.  DUBbing Down Translation: The Functional Interaction of Deubiquitinases with the Translational Machinery.

Authors:  Bandish B Kapadia; Ronald B Gartenhaus
Journal:  Mol Cancer Ther       Date:  2019-09       Impact factor: 6.261

Review 7.  The Mechanism and Function of Epigenetics in Uterine Leiomyoma Development.

Authors:  Qiwei Yang; Aymara Mas; Michael P Diamond; Ayman Al-Hendy
Journal:  Reprod Sci       Date:  2015-04-28       Impact factor: 3.060

8.  UCH-L1 in DLBCL: marker or target?

Authors:  Joseph S Pagano; Julia Shackelford
Journal:  Blood       Date:  2016-03-24       Impact factor: 22.113

9.  Ubiquitin carboxy-terminal hydrolase L1 may be involved in the development of mammary phyllodes tumors.

Authors:  Huang-Chun Lien; Chung-Chieh Wang; Chiun-Sheng Huang; Ya-Wen Yang; Wen-Hung Kuo; Yu-Tung Yao
Journal:  Virchows Arch       Date:  2013-01-05       Impact factor: 4.064

10.  Epidermal growth factor cytoplasmic domain affects ErbB protein degradation by the lysosomal and ubiquitin-proteasome pathway in human cancer cells.

Authors:  Aleksandra Glogowska; Jörg Stetefeld; Ekkehard Weber; Saeid Ghavami; Cuong Hoang-Vu; Thomas Klonisch
Journal:  Neoplasia       Date:  2012-05       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.